Cladribine in indolent non-Hodgkin’s lymphoma

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Harris NL. Mature B-cell neoplasms: introduction. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic Lymphoid Tissues. Jaffe ES (Ed.). IARC Press, Lyon, France (2001).
   Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N. Engl. J. Med.311(23), 1471–1475 (1984).
   PubMed Web of Science ®Google Scholar
• Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O’Connell MJ. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. Oncol.3(6), 769–775 (1985).
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Hancock BW et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet362, 516–522 (2003).
   PubMed Web of Science ®Google Scholar
• Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J. Clin. Oncol.22(8), 1454–1459 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and Iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J. Clin. Oncol.23(30), 7565–7573 (2005).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Weller E, Gascoyne RD et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 Phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood106, Abstract 349 (2005).
   Google Scholar
• Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood105(4), 1417–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung H et al. Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation? Biol. Blood Marrow Transplant.12, 641–647 (2006).
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Klasa R, Marcus R et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood108(10), 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Nadler L, Davies A et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J. Clin. Oncol.25(18), 2554–2559 (2007).
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Meyer RM, Shustik C et al. Randomized Phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin’s lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J. Clin. Oncol.20(24), 4649–4654 (2002).
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Eghbali H, Monfardini S et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin’s lymphoma. J. Clin. Oncol.24(10), 1590–1596 (2006).
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol.21(5), 891–896 (2003).
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol.13(3), 570–574 (1995).
   PubMed Web of Science ®Google Scholar
• Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet2(7786), 1076–1069 (1972).
   Google Scholar
• Cohen A, Hirschhorn R, Horowitz SD et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl Acad. Sci. USA75(1), 472–476 (1978).
   PubMed Web of Science ®Google Scholar
• Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J. Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with sever combined immunodeficiency disease. J. Clin. Invest.62, 884–887 (1978).
   PubMed Web of Science ®Google Scholar
• Polmar SH, Wetzler EM, Stern RC, Hirschhorn R. Restoration of in vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet2(7938), 743–746 (1975).
   PubMedGoogle Scholar
• Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phophorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl Acad. Sci. USA74(12), 5677–5681 (1977).
   PubMed Web of Science ®Google Scholar
• Hirschhorn R, Levytska V, Pollara B, Meuwissen HJ. Evidence for control of several different tissue-specific isozyme of adenosine deaminase by a single genetic locus. Nat. New Biol.246, 200–202 (1973).
   PubMedGoogle Scholar
• Christensen LF, Broom AD. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy-α- and -β-D-erythro-pentofuranosyl)purines. J. Med. Chem.15(7), 735–739 (1972).
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. USA77(11), 6865–6869(1980).
   PubMed Web of Science ®Google Scholar
• Vijayalakshmi DA, Belt JA. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. J. Biol. Chem.263, 19419–19423 (1988).
   PubMed Web of Science ®Google Scholar
• Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res.49, 4972–4978 (1989).
   PubMed Web of Science ®Google Scholar
• Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet340, 952–956 (1992).
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood62(4), 737–743 (1983).
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps T, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5´-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood81(3), 597–601 (1993).
   PubMed Web of Science ®Google Scholar
• Arner ES, Flygar M, Bohman C, Wallstrom B, Eriksson S. Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. Exp Cell Res.178, 335–342 (1988).
   PubMed Web of Science ®Google Scholar
• Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol.34, 485–491 (1988).
   PubMed Web of Science ®Google Scholar
• Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2´-deoxyadenosine 5-triphosphate into DNA during replication by human polymerases α and β. J. Biol. Chem.265(7), 4033–4040 (1990).
   PubMed Web of Science ®Google Scholar
• Hentosh P, Grippo P. Template 2-chloro-2´-deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol. Pharmacol.45, 955–961 (1994).
   PubMed Web of Science ®Google Scholar
• Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanisms of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest.75, 377–383 (1985).
   PubMed Web of Science ®Google Scholar
• Carson DA, Seto C, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism, and programmed cell death. Exp. Cell Res.164, 273–281 (1986).
   PubMed Web of Science ®Google Scholar
• Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature283, 593–596 (1980).
   PubMed Web of Science ®Google Scholar
• Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. In: Purine and Pyrimidine Metabolism in Man VII, Part A. Harkness RA (Ed.). Plenum Press, NY, USA 15–18 (1991).
   Google Scholar
• Robertson LE, Chubb S, Meyn RE et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2´-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood81(1), 143–150 (1993).
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood96(10), 3537–3543 (2000).
   PubMed Web of Science ®Google Scholar
• Leoni LM, Chao Q, Cottam HB et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2´-deoxyadenosine 5´triphosphate and cytochrome c. Proc. Natl Acad. Sci. USA95, 9567–9571 (1998).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2´-deoxyadenosine in humans. Cancer Res.51, 5570–5572 (1991).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2´-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol.10(10), 1514–1518 (1992).
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2´-deoxyadenosine. Proc. Natl Acad. Sci USA.81, 2232–2236 (1984).
   PubMed Web of Science ®Google Scholar
• Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol.10(3), 364–370 (1992).
   PubMed Web of Science ®Google Scholar
• Saven A, Kawasaki H, Carrera CJ et al. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol.11(4), 671–678 (1993).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2´-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin. Cancer Res.1, 385–390 (1995).
   PubMed Web of Science ®Google Scholar
• Beutler E, Piro LD, Saven A et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk. Lymphoma5, 1–8 (1991).
   PubMed Web of Science ®Google Scholar
• Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma10 (Suppl.), 133–138 (1991).
   Google Scholar
• Vahdat L, Wong ET, Wile MJ et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood84, 3429–3434 (1994).
   PubMed Web of Science ®Google Scholar
• Larson RA, Mick R, Spielberger RT, O’Brien SM, Ratain MJ. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J. Clin. Oncol.14(1), 188–195 (1996).
   PubMed Web of Science ®Google Scholar
• Hickish T, Serafinowski P, Cunningham D et al. 2´-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br. J. Cancer67(1), 139–143 (1993).
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol.10(3), 371–377 (1992).
   PubMed Web of Science ®Google Scholar
• Hoffman M, Tallman MS, Hakimian D et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.12(4), 788–792 (1994).
   PubMed Web of Science ®Google Scholar
• Morton J, Taylor K, Bunce I et al. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br. J. Haematol.95, 110–115 (1996).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin’s lymphoma. Leuk. Lymphoma25, 313–318 (1997).
   PubMed Web of Science ®Google Scholar
• Robak T, Gora-Tybor J, Krykowski E et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin’s lymphoma. Leuk. Lymphoma26, 99–105 (1997).
   PubMed Web of Science ®Google Scholar
• Kong LR, Huang CF, Hakimian D et al. Long term follow-up and late complications of 2-chlorodeoxadenosine in previously treated, advanced, indolent non-Hodgkin’s lymphoma. Cancer82(5), 957–964 (1998).
   PubMed Web of Science ®Google Scholar
• Tulpule A, Schiller G, Harvey-Buchanan LA et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin’s lymphoma. Cancer83(11), 2370–2376 (1998).
   PubMed Web of Science ®Google Scholar
• Tondini C, Balzarotti M, Rampinelli I et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin’s lymphoma: a Phase II randomized study. Ann. Oncol.11, 231–233 (2000).
   PubMed Web of Science ®Google Scholar
• Ogura M, Morishima Y, Kobayashi Y et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphomas: results of a Japanese Phase II study. Int. J. Hematol.80(2), 267–277 (2004).
   PubMed Web of Science ®Google Scholar
• Armitage JO, Tobinai K, Hoelzer D, Rummel MJ. Treatment of indolent non-Hodgkin’s lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int. J. Hematol.79(4), 311–321 (2004).
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer107(7), 1542–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br. J. Cancer79(7/8), 1215–1219 (1999).
   PubMed Web of Science ®Google Scholar
• Laurencet FM, Ballabeni P, Rufener B et al. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin’s lymphomas. Acta Haematol.117(1), 40–47 (2007).
   PubMed Web of Science ®Google Scholar
• Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.14(7), 2139–2144 (1996).
   PubMed Web of Science ®Google Scholar
• Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin’s lymphoma. Blood86(5), 1710–1716 (1995).
   PubMed Web of Science ®Google Scholar
• Betticher DC, Zucca E, von Rohr A et al. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin’s lymphoma. Ann. Oncol.7, 793–799 (1996).
   PubMed Web of Science ®Google Scholar
• Canfield VA, Vose J, Guiney P, Bennett B, Nichols C. 2-chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leuk. Lymphoma24, 335–339 (1997).
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jager G, Kienzer HR et al. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) – 2 h infusion for 5 days – as first-line treatment for advanced low grade non-Hodgkin’s lymphoma. Eur. J. Cancer34(10), 1560–1564 (1998).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Martinsson U, Cavallin-Stahl E et al. Cladribine for untreated or early low-grade non-Hodgkin’s lymphoma. Leuk. Lymphoma30, 573–581 (1998).
   PubMed Web of Science ®Google Scholar
• Blum KA, Johnson JL, Niedzwiecki D et al. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B study 9153. Cancer107(12), 2817–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Cheson B, Vena D, Barrett J, Friedlin B. Second malignancies as a consequence of nucleoside analogue therapy for chronic lymphoid leukemias. J. Clin. Oncol.17, 2454–2460 (1999).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E et al. Treatment of Waldenstrom Macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med.118(3), 195–198 (1993).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenstrom’s Macroglobulinemia with 2-chlorodeoxyadenosine. J. Clin. Oncol.12(12), 2694–2698 (1994).
   PubMed Web of Science ®Google Scholar
• Liu E, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinemia. Br. J. Haematol.103, 690–695 (1998).
   PubMed Web of Science ®Google Scholar
• Richards AI. Response of meningeal Waldenstrom’s Macroglobulinemia to 2-chlorodeoxyadenosine [Letter]. J. Clin. Oncol.13, 2476 (1995).
   PubMedGoogle Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood98(1), 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Leblond V, Levy V, Maloisel F et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood98(9), 2640–2644 (2001).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Chow KU, Jager E et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann. Oncol.10, 115–117 (1999).
   PubMed Web of Science ®Google Scholar
• Jager G, Neumeister P, Brezinschek R et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a Phase II study. J. Clin. Oncol.20(18), 3872–3877 (2002).
   PubMed Web of Science ®Google Scholar
• Dann EJ, Gillis S, Polliack A, Okon E, Rund D, Rachmilewitz EA. Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N. Engl. J. Med.329, 1547–1548 (1993).
   PubMedGoogle Scholar
• Zulian GB, Roux E, Tiercy JM et al. Transfusion-associated graft-versus-host disease in a patient treated with cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br. J. Haematol.89(1), 83–89 (1995).
   PubMed Web of Science ®Google Scholar
• Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep.70(10), 1225–1228 (1986).
   PubMedGoogle Scholar
• Hochster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin’s low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol.10(1), 28–32 (1992).
   PubMed Web of Science ®Google Scholar
• Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol.10(5), 790–794 (1992).
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.14(2), 514–519 (1996).
   PubMed Web of Science ®Google Scholar
• Eibschutz B, Baird SM, Weisman MH et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Arthritis Rheum.38(11), 1604–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother.5(6), 721–727 (2005).
   PubMedGoogle Scholar
• Juliusson G, Christiansen I, Hansen MM et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J. Clin. Oncol.14(7), 2160–2166 (1996).
   PubMed Web of Science ®Google Scholar
• von Rohr A, Schmitz SF, Tichelli A et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a Phase II study. Ann. Oncol.13(10), 1641–1649 (2002).
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Ratschiller D et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom’s macroglobulinemia. Swiss Group for Clinical Cancer Research (SAKK). Br. J. Haematol.99(2), 358–363 (1997).
   PubMedGoogle Scholar